Cytosurge AG
Ludovica Rizzo, PhD, currently serves as an Application Scientist at Cytosurge AG since November 2022. Prior to this role, Ludovica held positions as a researcher and PhD student at the University of Zurich from March 2019 to November 2022, where responsibilities included establishing new lab setups and investigating induced renal tubular epithelial cells in various 3D microenvironments. Previously, Ludovica was a Team Leader for the Life Science Zurich Young Scientist Network from January 2020 to October 2022 and a PhD student at the University of Freiburg from July 2018 to February 2019, focusing on similar cellular studies. Educational qualifications include a PhD in Tissue Engineering from the University of Zurich, a Master's degree in Cell, Tissue and Biotechnology from Politecnico di Milano, and a Bachelor's degree in Biomedical Engineering from the same institution.
This person is not in any offices
Cytosurge AG
Cytosurge AG, founded in 2009, is a biotechnology company that manufactures and distributes cutting-edge solutions based on its patented FluidFM® technology. At the heart of this technology are the hollow FluidFM Probes – the Micropipette, Nanopipette, and the Nanosyringe – specifically designed to offer a wide range of unique applications for single-cell manipulation in biology research. Cytosurge's current systems compatible with FluidFM probes include the FluidFM ADD-ON for AFM systems and the standalone semi-automated FluidFM OMNIUM system. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, contributing to human well-being through advancements in single-cell technologies. As the partner of choice for precision gene engineering cell line manufacturing, Cytosurge enables next-generation biologic production and cell and gene therapy treatments, empowering people to live longer and healthier lives. Cytosurge implements advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and the manufacturing of high-precision gene-engineered cell lines. With a unique single-cell workflow and dynamic gene expression analytics, Cytosurge manufactures advanced gene-engineered cell lines, empowering next-generation treatments to benefit human well-being.